Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): Stage 1 analysis of a randomised phase 3 study

The Lancet Oncology

Volumn 15, Issue 3, 2014, Pages 343-352

  Davies, Andrew ^a   Merli, Francesco ^b   Mihaljevic, Biljana ^c   Siritanaratkul, Noppadol ^d   Solal Céligny, Phillippe ^e   Barrett, Martin ^f   Berge, Claude ^h   Bittner, Beate ^h   Boehnke, Axel ^h   McIntyre, Christine ^g   MacDonald, David ⁱ  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Institut de Cancérologie de l'Ouest ^*  (France)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g Clinical Pharmacology Unit   (United Kingdom)

^h Clinical Development   (Switzerland)

ⁱ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GRADING; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INSOMNIA; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; VERTIGO; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84896723699     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70005-1     Document Type: Article

References (27)

1. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
2. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008, 26:4579-4586.
3. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG 1496 Study. J Clin Oncol 2009, 27:1607-1614.
4. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377:42-51.
5. Van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010, 28:2853-2858.
6. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009, 27:3994-4001.
7. Shpilberg O, Jackisch C Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer 2013, 109:1556-1561.
8. Goldenberg DM, Morschhauser F, Wegener WA Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010, 51:747-755.
9. Pivot X, Gligorov J, Müller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013, 14:962-970.
10. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768-773.
11. De Cock E, Kritikou P, Tao S, et al. Time savings with rituximab subcutaneous (SC) injection vs rituximab intravenous (IV) infusion: final analysis from a time-and-motion study in 8 countries. Blood 2013, 122. abstr 1742.
12. Salar A, Bouabdallah R, McIntyre C, Sayyed P, Bittner B A two-stage phase Ib study to investigate the pharmacokinetics, safety and tolerability of subcutaneous rituximab in patients with follicular lymphoma as part of maintenance treatment. Blood 2010, 116. abstr 2858.
13. Frost GI Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007, 4:427-440.
14. Yin A, Li J, Hurst D, Visich J Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 2010, 28(suppl):e13108.
15. Tobinai K, Igarashi T, Itoh K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 2004, 15:821-830. on behalf of the IDEC-C2B8 Japan Study Group.
16. Bittner B, Richter WF, Hourcade-Potelleret F, et al. Development of a subcutaneous formulation for trastuzumab-nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Drug Res 2012, 62:401-409.
17. Bittner B, Richter WF, Hourcade-Potelleret F, et al. Development of a subcutaneous formulation for trastuzumab-nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Erratum. Drug Res 2013, 63:602.
18. Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner N Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 2013, 53:192-201.
19. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012, 13:869-878.
20. Keating M, O'Brien S High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol 2000, 27(suppl 12):86-90.
21. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165-2170.
22. Egorin MJ Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target. J Clin Oncol 2003, 21:182-183.
23. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?. Oncologist 2007, 12:913-923.
24. Wang DD, Zhang S, Zhao H, Men AY, Parivar K Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009, 49:1012-1024.
25. Salar A, Avivi I, Larouche J-F, et al. Final results of the BP22333 study demonstrate non-inferior pharmacokinetics (PK) and safety of subcutaneous (SC) administration of rituximab compared with intravenous (IV) administration as maintenance therapy in patients with follicular lymphoma (FL). Blood 2012, 120. abstr 1641.
26. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol 1999, 17:1244.